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For patients with T2 glottic cancer, con-
servative surgery, radiation therapy (RT) 
or a combination of both are considered 
standard therapy. The choice of treat-
ment is based on the physician’s experi-
ence, hospital policy and patient willing-
ness. In most centers however, RT is the 
initial treatment prescribed for T2 glottic 
lesions, with surgery reserved for salvage 
after RT failure. Although hemilaryngec-
tomy or cordectomy produce comparable 
cure rates for selected T2 vocal cord le-
sions, RT is generally preferred: the major 
advantage of RT cover partial laryngecto-
my is better posttreatment voice quality 
[9–11].
The TNM disease stage is useful for 
surgeons, but not necessarily for radia-
tion oncologists. The essential effect of 
radiation is cell killing. The degree of cell 
killing to be achieved depends on the ini-
tial number of cancer cells and dose frac-
tionation planning should thus be tailored 
to this parameter. The T stage according 
to the Union for International Cancer 
Control (UICC) TNM classification sys-
tem may not correlate with RT outcome 
if the same total dose is delivered to a giv-
en stage of cancer: different tumors of 
the same stage can differ significantly in 
terms of the initial number of cancer cells 
[1, 3]. It seems that for many tumors, par-
ticularly in the head and neck region, vol-
umetric staging might be a more precise 
numerical parameter than TNM. At least 
for head and neck cancer, a number of au-
thors have found a significant correlation 
between initial tumor volume (TV) and 
local tumor control (LTC) after RT [2, 4–
7]. However, the majority of available da-
ta represent heterogeneous groups of pa-
tients, mostly in advanced stages of dis-
ease, with a relatively wide range of TVs. 
Among laryngeal tumors, the T2 stage of 
glottic cancer refers to infiltration of the 
larynx and impaired vocal cord mobility, 
irrespective of the wide spectrum of TVs. 
Therefore, the present study aims to ana-
lyze the impact of variation in initial TV 
on RT outcome in T2 glottic cancer.
Materials and methods
Patient characteristics
The study included 115 previous-
ly untreated consecutive patients with 
T2N0M0 glottic cancer who were treat-
ed with RT alone between 2002 and 2009. 
There were 104 men (91 %) and 11 wom-
en (9 %); age 40–80 years (mean 61 years). 
The clinical diagnosis of T2 glottic can-
cer was based on CT examination supple-
mented with information concerning tu-
mor spread or superficial infiltration, as 
obtained upon endoscopic laryngeal ex-
amination. Neither positron-emission to-
mography (PET) nor MRI was routinely 
performed. Extension of the tumor into 
supraglottic regions was found in all cas-
es. Impaired vocal cord mobility was not 
observed in isolation. In terms of histo-
pathology, there were 24 (21 %) and 45 
(39 %) well (G1) and poorly (G2, G3) dif-
ferentiated tumors, respectively; in 46 pa-
tients (40 %), no data on this was avail-
able. Human papillomavirus (HPV) sta-
tus was not examined in this group of pa-
tients.
In all cases, the primary TV was con-
toured on contrast-enhanced CT scans 
(3 mm slices). TV (cm3) was calculated 
using the volume algorithm of the Eclipse 
Treatment Planning System (Varian 
Medical Systems, Palo Alto, CA, USA). 
TV ranged from 0.16 to 17 cm3 (tumor di-
ameter: 0.34–3.2 cm). Median hemoglo-
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Table 1 Dependence of local tumor control (LTC) on initial tumor volume (TV) in T2 glottic 
cancer
TV group No. cases TV (cm3) Diameter (cm) Failure LTC 3-year LTC
PT LR
A 9  ≤ 0.28  ≤ 0.8 1 – 8 89 %
B 32 0.29–0.7 0.81–1.1 – 5 27 84 %
C 33 0.71–1.76 1.11–1.5 3 4 26 78 %
D 21 1.77–3.6 1.51–1.9 7 2 12 57 %
E 12 1.61–8.2 1.91–2.5 4 1 7 58 %
F 8 8.21–17.1 2.51–3.2 4 2 2 25 %
Intergroup comparisons
TV groups P-value
(A + B) vs. (C + D) 0.05
(C + D) vs. (E + F) < 0.05
(A + B) vs. (E + F) < 0.005
PT persistent tumor, LR local recurrence
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bin concentrations before (Hb0) and after 
RT (Hb1) were 14.8 and 13.9 g/dl, respec-
tively. An additional parameter represent-
ing the individual difference between Hb1 
and Hb0, ΔHb, was also calculated. The 
median ΔHb was − 1.2 g/dl, (range − 4.6–
1.1 g/dl). Hemoglobin concentration was 
not corrected in any way, neither before 
nor during RT.
Treatment
All patients were treated using the three-
dimensional intensity-modulated RT 
(3D IMRT) technique. The planning tar-
get volume (PTV) corresponded to treat-
ment of the primary tumor with a mini-
mum margin of 1 cm, to compensate for 
laryngeal motion. The high-dose clinical 
target volume (CTV) involved the major-
ity of the larynx and involved nodes with a 
1 cm margin. Remaining nodal levels were 
encompassed in the elective-dose CTV.
Total fractionated dose ranged from 45 
to 74 Gy, given within an overall treatment 
time (OTT) ranging from 28 to 57 days. 
Because the dose per fraction ranged be-
tween 1.8 and 3 Gy, total dose was recalcu-
lated as the normalized total dose (NTD) 
if given in 2.0-Gy fractions (Gy2) using a 
linear-quadratic model (with an α/β val-
ue of 10.0 Gy).
End points and statistics
The follow-up was at least 3 years. Cases 
lost from observation were censored. LTC 
was scored if there was no evidence of dis-
ease during at least 3 years. Local failure 
was defined either as persistent tumor 
(PT) at the completion of the RT or as lo-
cal recurrence (LR) if disease reoccurred 
during follow-up after complete tumor 
clearance at the end of RT. Actuarial dis-
ease-free (DFS) and overall (OS) survival 
were calculated using the Kaplan–Meier 
statistic and the differences were assessed 
by the log-rank test. Raw data were used 
to analyze the relationship between NTD, 
TV and tumor cure probability (TCP). 
To evaluate the impact of TV and other 
clinical and treatment parameters (age, 
symptom duration, NTD, OTT, ΔHb) on 
treatment outcome (i.e. TCP), univariate 
analysis was first used. Variables which 
reached significance in this first step were 
then analyzed by multivariate Cox regres-
sion. A p-value of 0.05 was accepted as the 
level of significance.
Results
Overall 3-year LTC was 71 %. There were 
19 instances of PT (17 %) after RT and 14 
cases of LR (12 %).
Relationship between TV and LTC
Data were subdivided into six groups (A–
F), depending on TV. LTC rates and the 
incidence of failure in relation to initial 
TV are shown in . Table 1. A strong and 
significant correlation of LTC with initial 
TV was observed. A sixfold increase in 
initial TV (on average from 0.5 to 3 cm3) 
translated into a decrease in LTC of about 
30 % (from 89 to 57 %; . Fig. 1). The sig-
nificant correlation of TV with LTC was 
apparent when these were treated both 
as continuous and as categorized vari-
ables. A decrease in TV from about 17.1 
to 0.5 cm3 leads to a threefold increase in 
LTC (from 25 to 84 %). Similarly, for tu-
mors with TV > 1.6 cm3, the risk of local 
failure was almost four times higher than 
for the TV ≤ 0.5 cm3 (. Table 2).
Among the factors and parameters an-
alyzed using the multivariate Cox mod-
el, ΔHb and TV were found to be signif-
icant independent risk features for local 
failure. An increase in ΔHb of 1 g/dl dur-
ing the course of RT decreased the risk of 
local failure by 36 %. Independent of oth-
er factors, tumors with a TV larger than 
1.6 cm3 had a significantly (threefold) 
higher risk of local failure than smaller 
tumors (. Table 3).
Radiobiological rationale and 
the TV–NTD–LTC relationship
Actuarial DFS as a function of TV is illus-
trated by the Kaplan–Meier plot shown in 
. Fig. 2. Raw data points for 3-year LTC, 
PT and LR are plotted within the coordi-
nates of initial TV and NTD in . Fig. 3. 
Except for 9 cases, NTD data points are 
distributed within a relatively narrow 
range of 65–73 Gy.
The effective D0 (effD0) is the dose 
which reduces cell survival by one natu-
ral logarithm (e−1) for a particular frac-
tionation regimen. For analysis of clinical 
data it is more useful to replace effD0 with 
D10, which is the dose that reduces sur-
vival by one common logarithm. An effD0 
of 2.8 Gy was selected (acceptable aver-
age value for small head and neck squa-
mous cell tumors), which corresponds to 
a D10 of 6.5 Gy [7]. For tumors 0.5 cm in 
diameter (109 cells), an NTD of 65 Gy2.0 






























Fig. 1 8 Measured 3-year local tumor control (LTC) of T2 glottic cancer as a function of tumor volume 
(TV). Circles are proportional to the number of cases, squares represent each of two-subgroups)
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If the number of tumor cells increases by 
one order of magnitude to 1010 (5 cm3), 
then a similarly effective NTD should be 
71.5 Gy. Based on these assumptions, a 
theoretical iso-NTD85 (NTD required 
to give a 3-year LTC of 85 %) curve has 
been plotted (. Fig. 3). At first glance, the 
iso-curve does not clearly separate con-
trol cases from failures because total dos-
es were designed based on T stage, not 
on TV. However, it fits to the data set 
quite well. For small tumors (≤ 0.5 cm3) 
the NTD of 65 Gy2.0 gives a 3-year TCP 
of about 84 % (10/12) and for tumors 
with a tenfold larger volume (and with 
the cell number increased by one order 
of magnitude) the TCP is around 100 % 
if the NTD increases to 71.5 Gy2.0. Using 
the curve shown in . Fig. 3, 3-year LTC 
rates were calculated in relation to a given 
NTD (. Table 4). The NTD of 67 ± 2 Gy2.0 
gave rise to a calculated 93 % 3-year LTC 
for very small tumors (tumor cell num-
ber ≤ 109), which decreases significantly 
(p < 0.0001) to 33 % for 2–2.5 cm tumors 
and even further to 14 % for tumors larg-
er than 3 cm. At an NTD of 72 ± 2 Gy2.0, 
the 3-year LTC was 100 % for both small 
and larger tumors.
Discussion
The fundamental goal of radical (not pal-
liative) RT is to kill the last surviving can-
cer cell: if a single cell survives, local fail-
ure can likely be expected and the entire 
dose would have been “wasted”. Logi-
cally, the total dose and its fractionation 
should be tailored to the initial number 
of tumor cells, which more strongly cor-
relates with TV than with tumor diame-
ter or T stage. If tumor diameter doubles 
(e.g. 1–2 or 2–4 cm), TV increases eight-
fold and the cell number increases by 
about one order of magnitude. The de-
sign of dose fractionation schemes for in-
dividual patients depends on the clinical 
and, ever increasingly, on the molecular 
profile of the tumor, although TNM stage 
still plays major role. However, there is a 
relatively large variation in TV within a 
given T stage (N0M0) and it seems illog-
ical to prescribe the same total dose to all 
tumors within a single T category.
The present study comprises a clinically 
homogenous group of 115 T2N0M0 glot-
tic cancers and demonstrates a significant 
correlation between 3-year LTC and initial 
TV. An increase in TV from about 0.3 to 
17 cm3 resulted in a decrease in 3-year LTC 
from 89 to 25 % (. Fig. 1). Moreover, for 
patients with a TV of 1.6 cm3, the risk of 
local failure was four times higher than for 
those with a TV of 0.5 cm3. TV has been 
identified as a significant independent 
predictor for treatment outcome (Tables 2 
and 3). This relationship also has a signifi-
cant impact on 3-year DFS, which was sig-
nificantly lower (about twofold) for larg-
er tumors than for smaller ones. The prog-
nostic impact of both TV and hemoglobin 
concentration on the outcome of patients 
with head and neck cancer was reported 
by Rudat et al. [12] in 68 patients with ad-
vanced tumors treated with chemoradio-
therapy. The significant influence of Hb0 
and Hb1 concentrations on RT outcome 
for patients with T2 glottic and epiglot-
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Abstract
Background. The aim of this study was to 
quantify the impact of initial tumor volume 
(TV) on radiotherapy (RT) outcome in pa-
tients with T2 glottic cancer.
Materials and methods. Initial TV was cal-
culated for 115 consecutive patients with T2 
glottic cancer who had been treated with de-
finitive RT alone at a single institution.
Results. The results showed strong corre-
lations of TV with 3-year local tumor con-
trol (LTC) and disease-free survival (DFS). 
For TV ≤ 0.7 cm3, 3-year LTC was 83 %; for TV 
0.7–3.6 cm3 this was 70 % and for TV 3.6–
17 cm3 44 %. Analysis of total dose vs. initial 
TV showed that larger T2 glottic tumors with 
a TV of around 5 cm3 (2–2.5 cm in diameter 
with 1010 cancer cells) need an extra 6.5 Gy 
to achieve similar 3-year LTC rates as for small 
tumors with a TV of 0.5 cm3 (~ 1 cm in diame-
ter with 109 cancer cells).
Conclusion. Although classification of tu-
mors according to TV cannot replace TNM 
staging in daily practice, it could represent a 
valuable numerical supplement for planning 
the optimal dose fractionation scheme for in-
dividual patients.
Keywords
TNM staging · Dose fractionation · Survival · 
Radiation oncologist · Intensity-modulated 
radiation therapy
Einfluss des anfänglichen Tumorvolumens auf das Be-
strahlungsergebnis bei Patienten mit T2-Glottiskrebs
Zusammenfassung
Hintergrund. Ziel der vorliegenden Stu-
die ist quantitative Bestimmung des Einflus-
ses des anfänglichen Tumorvolumens (TV) 
auf die Ergebnisse der Strahlentherapie (RT) 
bei Patienten mit Glottiskrebs im Krankheits-
stadium T2.
Material und Methoden. Das anfängliche 
TV wurde bei 115 nachfolgenden Patienten 
mit Glottiskrebs im Krankheitsstadium T2 ge-
messen, die ausschließlich mit RT in einer ein-
zigen Einrichtung behandelt wurden.
Ergebnisse. Die Ergebnisse ergaben eine 
starke Korrelation von TV mit dem Ergeb-
nis der 3-jährigen lokalen Tumorkontrol-
le (LTC) und dem krankheitsfreien Überle-
ben (DFS). Für TV ≤ 0,7 cm3 betrug das Er-
gebnis der 3-jährigen LTC 83 %, und entspre-
chend 70 % für TV 0,7–3,6 cm3 und 44 % für 
TV 3,6–17 cm3. Die Analyse der Gesamtdosis 
im Vergleich zum anfänglichen TV ergab, dass 
im Bereich des Glottiskrebs im Krankheits-
stadium T2 größere Tumoren mit einem TV 
von etwa 5 cm3 (2–2,5 cm Durchmesser mit 
1010 Tumorzellen) die Anwendung von zusätz-
lichen 6,5 Gy erfordern, um eine vergleichba-
re 3-jährige LTC wie bei kleinen Tumoren mit 
einem TV von 0,5 cm3 (~ 1 cm Durchmesser 
mit 109 Tumorzellen) zu erreichen.
Schlussfolgerung. Obwohl in der täglichen 
Praxis die Klassifizierung nach Tumorvolu-
men die TNM- Klassifizierung nicht ersetzen 
kann, könnte sie für einzelne Patienten eine 
wertvolle zahlenmäßige Ergänzung für die 
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tic tumors had been also reported pre-
viously; furthermore, a significant neg-
ative correlation between Hb0, Hb1 and 
TV was noticed in this group of patients 
[13]. The correlation between TV and 
treatment outcome after RT has also been 
documented by other authors: Lo et al. [6] 
noted a significantly higher risk of local 
failure in T2 glottic cancer for TV great-
er than 4 cm3 (~ 2 cm in diameter). Kraas 
et al. [4]) chose their cutoff TV at 6 cm3 
and measured the 2-year LTC for small-
er tumors at 67 % compared with 43 % for 
larger ones (p = 0.07). For the same cutoff 
TV, Mancusco et al. [7] noted LTC rates 
of 83 and 46 % for smaller vs. larger tu-
mors, respectively. A study by Hamilton 
et al. [2] focused on small glottic tumors 
showed 88 % vs. 31 % LTC rate for glottic 
tumors with TV smaller and larger than 
1 cm3 (1.2 cm in diameter), respectively. 
However, the latter analysis consisted of 
only 50 cases. The results cited above cor-
respond to those of the present study. The 
major difference is that other authors have 
used arbitrary TV cut off levels, whereas 
in the present study, the TV has been an-
alyzed as a continuous variable. Using TV 
cutoffs we noted a 3-year LTC of 85 % for 
TV ≤ 0.7 cm3, 70 % for TV of 0.7–3.6 cm3 
and 45 % for TV of 3.6–17 cm3.
All these studies require very careful 
interpretation, since the dose fraction-
ation for individual patients was likely 
designed mainly on the basis of T catego-
ry, with TV not being considered as an 
important pretreatment determinant (at 
least not in the way presented here).
On the other hand, for relatively small 
T2N0M0 glottic tumors it is hard to be-
lieve that hypoxia and repopulation may 
have important impact on the response 
to a given NTD. If the NTD is more or 
less constant, the difference in the initial 
number of tumor cells (various TV) may 
be a predominant factor. The wide spread 
of individual NTD data points within 
each of the TV compartments is shown 
in . Fig. 3. This demonstrates that total 
doses were not designed according to ini-
tial TV, but were likely intuitively larger 
for small but infiltrating tumors. For an 
NTD of 65 Gy2.0, failures were observed 
for tumors with TV > 4 cm3; whereas for 
67 Gy2.0, all tumors with TV ≤ 8 cm3 were 
locally controlled. Despite some uncer-
tainties, the volume–dose–response rela-
tionship fits radiobiological rationale. The 
theoretical iso-curve in . Fig. 3 fits to the 
analyzed data set quite well. An NTD of 
67 ± 2 Gy2.0 produced a 3-year LTC of 
93 % for small T2 glottic cancer with a 
TV of 0.5 cm3 (1 cm in diameter) or less. 
For larger tumors with a TV of ≥ 5 cm3 
(≥ 109.8 cells), the 3-year LTC was signif-
icantly (p < 0.0001) lower at 33 %. Deliv-
ery of an NTD of 72 ± 2 Gy2.0 gave rise to 
100 % 3-year LTC, independent of tumor 
volume. Therefore it seems reasonable to 







































































































Fig. 2 8 Actuarial disease-free survival (DFS) as a function of initial tumor volume (TV). Significant dif-
ferences between groups A + B (blue solid line), C + D (red dashed line) and D + E (green dotted line)
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cer, a tenfold increase in TV (increase in 
the number of tumor cells of about one 
order of magnitude) needs an extra dose 
of about 6.5 Gy to achieve similarly high 
3-year LTC.
Volumetric staging quantified by mea-
surement and calculation of TV will not 
replace TNM staging, but it can be a valu-
able numerical supplement for designing 
optimal dose fractionation planning for 
individual patients.
Conclusion
Despite some limitations, the present 
study clearly documents the significant 
impact of initial TV on the RT response 
of T2N0M0 glottic cancers. Although 
the size of the total dose was not de-
signed in relation to TV, a significant vol-
ume–dose–response relationship was 
noted. The TV measurements do not re-
place TNM categories, but could provide 
a valuable numerical supplement for 
the design of optimal dose fractionation 
schemes for individual patients.
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Appendix
Poissone statistics correlate tumor control 
probability (TCP) with cell survival rate 
as follows:
 (1)
Where x is the average number of surviv-
ing cancer cells per tumor, which results 
from multiplication of initial cell number 
(IC) by the surviving fraction (SF).
Simple relationship between SF and a 
given total dose formula:
 (2)
Where effD0 reduces survival rate to e−1
For analysis of clinical data is more 
useful to replace effD0 by D10, which re-
duces SF by one order of magnitude and 
it equals:
 (3)
Example: if IC = 109 cancer cells (0.5 cm3 
tumor) than TD = 10 x D10 is needed to 
achieve x = 0.1, which gives TCP = 90 %.
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terms of the Creative Commons Attribution License 
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tion in any medium, provided the original author(s) 
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Table 4 Calculated 3-year local tumor 
control (LTC) of T2N0M0 glottic cancer 
related to tumor volume (TV), i.e. no. cells, 
diameter and total NTD
No. tumor 
cells/diameter
3-year local tumor control
67 ± 2 Gy2.0 72 ± 2 Gy2.0
≤ 109 ( ≤ 1 cm) 93 % (13/14) 100 % (3/3)
109.8–1010.1 
(2–2.5 cm)
33 % (5/15) 100 % (9/9)
1010.1–1010.6 
(3–5 cm)
14 % (1/7) 100 % (3/3)
Table 2 Local failure hazard ratio in rela-
tion to tumor volume
TV (cm3) HR 95 % CI P-value
≤ 0.5 1 – –
> 0.5– ≤ 1 1.19 0.26–4.54 0.8
> 1– ≤ 1.6 1.77 0.39–8.09 0.4
> 1.6 3.93 1.06–14.54 0.03
HR hazard ratio, CI confidence intervals, TV tumor 
volume
Table 3 Results of multivariate analysis in 
terms of local failure hazard ratio
Variable HR 95 %CI P-value
Age 1.03 0.96–1.10 0.3
ΔHb 0.64 0.40–1.02 0.05
TV (> 1.6 cm3) 3.21 1.07–9.63 0.03
HR hazard ratio, CI confidence intervals, ΔHb dif-
ference in hemoglobin concentrations before and 
after radiotherapy, TV tumor volume
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